Replies to post #134430 on Biotech Values

[mcbio]

I still do not follow the connection. Unless there is more than the statement, I sense some disappointment over their own program. Moreover, all trials will be checking for cancers, etc. Regardless, the path to approval on CVD is long and expensive.

I thought you were suggesting this issue (malignancy risk) may be an issue for ISIS' entire antisense approach and pipeline when I think it seems more specific to the target (PCSK9) and just one of their drugs.